Clinical trials
Withdrawn trials in Israel
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
266 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 17 |
| 2007 | 8 |
| 2008 | 18 |
| 2009 | 17 |
| 2010 | 13 |
| 2011 | 21 |
| 2012 | 21 |
| 2013 | 19 |
| 2014 | 18 |
| 2015 | 13 |
| 2016 | 12 |
| 2017 | 7 |
| 2018 | 11 |
| 2019 | 7 |
| 2020 | 10 |
| 2021 | 7 |
| 2022 | 8 |
| 2023 | 6 |
| 2024 | 4 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 266 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hadassah Medical Organization | 44 |
| Sheba Medical Center | 27 |
| Rambam Health Care Campus | 19 |
| HaEmek Medical Center, Israel | 15 |
| Meir Medical Center | 15 |
| Rabin Medical Center | 14 |
| Carmel Medical Center | 5 |
| Beersheva Mental Health Center | 4 |
| EarlySense Ltd. | 4 |
| Shaare Zedek Medical Center | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 10 |
| Myelodysplastic Syndromes | 5 |
| Schizophrenia | 5 |
| Burns | 4 |
| Crohn Disease | 4 |
| Diabetes Mellitus, Type 1 | 4 |
| Obesity | 4 |
| Pain | 4 |
| Anxiety Disorders | 3 |
| Colitis, Ulcerative | 3 |
Trials
Showing 26 to 50 of 266. Each trial links to its page on Pharma Observatory.
166 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.